BRIEF published on 09/18/2024 at 07:05, 1 year 5 months ago Relief Therapeutics Completes Clinical Phase of RLF-OD032 Study Clinical Study Bioavailability RLF-OD032 Phenylketonuria Sapropterin Dihydrochloride
PRESS RELEASE published on 09/18/2024 at 07:00, 1 year 5 months ago Relief Therapeutics Completes Clinical Phase in RLF-OD032 Proof-of-Concept Study; Topline Results Expected in October 2024 Relief Therapeutics completes clinical phase in RLF-OD032 proof-of-concept study for PKU treatment, expecting topline results in October 2024 Relief Therapeutics RLF-OD032 Proof-of-Concept Study PKU Treatment Topline Results
BRIEF published on 09/02/2024 at 07:05, 1 year 6 months ago Relief Therapeutics Announces PKU GOLIKE Study Results Presentation at SSIEM 2024 Clinical Trial Relief Therapeutics PKU GOLIKE SSIEM 2024 Phenylketonuria
PRESS RELEASE published on 09/02/2024 at 07:00, 1 year 6 months ago Relief Therapeutics Announces PKU GOLIKE Study Results Presentation at SSIEM 2024 Relief Therapeutics announces interim results of PKU GOLIKE study at SSIEM 2024, showing potential benefits for phenylketonuria patients. Study evaluates overnight Phe fluctuations Clinical Trial Relief Therapeutics PKU GOLIKE SSIEM 2024 Phenylketonuria
BRIEF published on 08/30/2024 at 07:05, 1 year 6 months ago Relief Therapeutics Reports Half-Year 2024 Financial Results and Corporate Update Financial Results Revenue Increase Clinical Trials Corporate Update Cash Reserves
PRESS RELEASE published on 08/30/2024 at 07:00, 1 year 6 months ago Relief Therapeutics Reports Half-Year 2024 Financial Results and Provides Corporate Update Relief Therapeutics reports half-year 2024 financial results and provides corporate update, showcasing operational progress, key development programs, and financial stability Half-year Results Relief Therapeutics Financial Update Development Programs Cash Reserves
BRIEF published on 08/05/2024 at 07:05, 1 year 6 months ago Relief Therapeutics Secures Up to $11 Million from Royalty Sales FDA Approval Clinical Development Relief Therapeutics Non-dilutive Funding Royalty Sales
PRESS RELEASE published on 08/05/2024 at 07:00, 1 year 6 months ago Relief Therapeutics Secures up to $11 Million from Royalty Sales Relief Therapeutics secures $11 million from royalty sales for RLF-TD011 clinical development and pipeline advancement. Funding from SWK Holdings Corporation to support rare disease treatment options SWK Holdings Corporation Clinical Development Relief Therapeutics Rare Diseases Royalty Sales
BRIEF published on 06/27/2024 at 12:50, 1 year 8 months ago Relief Therapeutics Holding SA Reports Results of Annual General Meeting Board Of Directors Shareholders Financial Statements Relief Therapeutics AGM Results
PRESS RELEASE published on 06/27/2024 at 12:45, 1 year 8 months ago RELIEF THERAPEUTICS Holding SA Announces Results of Annual General Meeting RELIEF THERAPEUTICS Holding SA announces the results of its Annual General Meeting of Shareholders in Geneva. Details on approved resolutions and election outcomes Annual General Meeting Shareholders Resolutions RELIEF THERAPEUTICS Holding SA Geneva
Published on 03/03/2026 at 14:08, 12 minutes ago Datavault AI Reports Significant Institutional Ownership Growth as Platform Expansion Accelerates
Published on 03/03/2026 at 14:00, 20 minutes ago Click Media, a GameSquare Company, Wins Influencer Management Agency of the Year
Published on 03/03/2026 at 13:00, 1 hour 20 minutes ago Alta Copper Issues Update on Fortescue Transaction
Published on 03/03/2026 at 13:00, 1 hour 20 minutes ago NextSource Materials Extends Mitsubishi Chemical Offtake Agreement Timelines
Published on 03/03/2026 at 14:05, 14 minutes ago Akash Systems Announces World's First Diamond Cooled AI Servers with AMD Instinct™ MI350X GPUs and MiTAC Computing
Published on 03/03/2026 at 14:05, 14 minutes ago Addepar Unveils Addison, a Native AI Experience Built to Deliver Actionable Intelligence Across Investment Workflows
Published on 03/03/2026 at 13:59, 21 minutes ago BEX Global Welcomes NYSE into the 24/7 Tokenized Era: “Validation of the Vision We Pioneered”
Published on 03/03/2026 at 13:00, 1 hour 19 minutes ago Now Is Yours: Huawei Redefines Smart Living at MWC 2026
Published on 03/03/2026 at 12:30, 1 hour 50 minutes ago Immunic to Participate in Investor Conferences in March
Published on 03/03/2026 at 09:57, 4 hours 23 minutes ago Disclosure of shares outstanding and voting rights - 03.03.2026
Published on 03/03/2026 at 07:00, 7 hours 20 minutes ago Thales makes available its 2025 Financial Statements
Published on 03/03/2026 at 07:00, 7 hours 20 minutes ago Thales reports its 2025 full-year results - press release - 3rd March 2026
Published on 03/02/2026 at 17:35, 20 hours 45 minutes ago Disclosure of transactions in own shares from February 23 to February 27, 2026
